NCT01025700 is a Phase 2/Phase 3 clinical trial of Cesemat in Marijuana Smoking, sponsored by University of British Columbia.

Who is sponsoring NCT01025700?

NCT01025700 is sponsored by University of British Columbia.

What drugs are being tested in NCT01025700?

Interventions in NCT01025700: Cesemat.

What condition does NCT01025700 study?

NCT01025700 studies Marijuana Smoking.

Is NCT01025700 still recruiting?

NCT01025700 is currently completed. Last updated 16 February 2011.

Last reviewed 2011-02-16 · How we verify

NCT01025700

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Double-Blind Placebo Control Study on the Use of Nabilone for Outpatient Management of Acute Marijuana Withdrawal

Completed Phase 2/Phase 3 Last updated 16 February 2011

What this trial tests

Phase 2/Phase 3 trial testing Cesemat in Marijuana Smoking in 35 participants. Completed in 1 October 2010.

Timeline

1 June 2009

Primary endpoint
1 June 2010

1 October 2010

Quick facts

Lead sponsor	University of British Columbia
Phase	Phase 2/Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	35
Start date	1 June 2009
Primary completion	1 June 2010
Estimated completion	1 October 2010
Sites	1 location across Canada

Drugs / interventions tested

Cesemat — full drug profile →

Conditions studied

Marijuana Smoking — all drugs for Marijuana Smoking →

Sponsor

University of British Columbia

Who can join

Adults 19 to 65, any sex, with Marijuana Smoking. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Safety and tolerability to Nabilone

Sponsor's own description

Safety of Nabilone in reducing marijuana craving

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Marijuana Smoking

Currently open trials in the same condition.

NCT03909477 — Longitudinal Study of Xenon-129 MRI Imaging Effects of Cannabis Smoking · recruiting

Other University of British Columbia trials

Trials by the same sponsor.

NCT07340970 — Sensory Stimuli During Cesarean Delivery · not yet recruiting
NCT07481201 — Phenylalanine Requirements in the Menstrual Phases · NA · not yet recruiting
NCT07492095 — Leucine Requirements in School-Age Children · NA · not yet recruiting
NCT07429305 — Combined Tibial Nerve Stimulation and Standing for People With SCI · NA · recruiting
NCT07519928 — Exploring the Feasibility and Benefits of Implementing Pelvic Floor Muscle Training During Inpatient Rehabilitation for · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01025700 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of British Columbia
Last refreshed: 16 February 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01025700.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing